Arcadia Biosciences (RKDA) Q3 2024 earnings summary

Executive summary

• Total revenues increased 18% year-over-year in Q3 2024, driven by a 55% surge in Zola coconut water sales and expanded distribution.

• Zola now represents 86% of total revenues, with significant distribution gains and strong in-store demand.

• Net loss for Q3 2024 was $1.6 million ($1.18/share), a 37% improvement from Q3 2023.

• Operating cash use declined to $1.5 million, the lowest since going public, reflecting improved cost management.

• GoodWheat brand and RS durum wheat trait were sold in Q2 2024, generating $7.7 million in cash and a $4.0 million gain.

Financial highlights

• Q3 2024 revenues: $1.54 million, up from $1.30 million in Q3 2023.

• Q3 2024 net loss: $1.61 million ($1.18/share) vs. $2.57 million ($1.89/share) in Q3 2023.

• SG&A expenses were $2.2 million, with $380,000 in transition costs from the GoodWheat sale and severance expenses.

• Ended Q3 with $3.9 million in cash and $2.6 million in short-term investments.

• Gross margin improved due to gain on sale of intangible assets and lower operating expenses.

Outlook and guidance

• No specific forward-looking guidance provided due to the timing and scale of new distribution.

• Full-year 2024 retail distribution growth for Zola expected to exceed 80%.

• Management expresses substantial doubt about ability to continue as a going concern for the next 12-18 months without additional funding.

• Plans to scale Zola through retail expansion and evaluate M&A opportunities.

• New product innovation for Zola is planned for launch in the next beverage season.